A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2022-04-28
Adverse events
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-07-15 (study day 63); relationship: not assessed
Grade 2 Alopecia — outcome: UNKNOWN; onset 2022-10-14 (study day 154); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-31 (study day 171); relationship: not assessed
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-01-11 (study day 243); relationship: not assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-05-01 (study day 353); relationship: not assessed
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-05-09 (study day 361); relationship: not assessed
Data queries
No data queries.